[Comment] Treatment of Uncomplicated Lower Urinary Tract Infections in Women

Why It Matters

Choosing the most effective short‑course antibiotic reduces treatment failures, limits unnecessary exposure, and supports antimicrobial stewardship in primary care.

Key Takeaways

• Half of women experience at least one UTI in their lifetime
• Single‑dose fosfomycin shows lower cure rates than 5‑day nitrofurantoin in recent trials
• Nitrofurantoin remains first‑line per 2025 EAU guidelines for uncomplicated cystitis
• Fosfomycin resistance stays low, yet urinary concentrations vary widely among patients
• Short‑course antibiotics aid stewardship but must ensure comparable efficacy and safety

Pulse Analysis

Urinary tract infections remain one of the most common bacterial ailments in women, with epidemiological surveys indicating that roughly 50% will experience at least one episode during their lives. Because the infections are typically uncomplicated, clinical guidelines have long advocated short oral regimens—single‑dose fosfomycin, five‑day nitrofurantoin, or three‑day pivmecillinam—to minimize drug exposure while achieving rapid symptom relief. The European Association of Urology’s 2025 guidelines still list nitrofurantoin as the preferred first‑line agent, reflecting its robust efficacy record and favorable safety profile.

The therapeutic hierarchy, however, has been shaken by recent head‑to‑head trials. Huttner et al.’s 2018 JAMA study and the multicentre SCOUT trial published in 2026 both reported statistically lower clinical cure rates for single‑dose fosfomycin compared with a five‑day nitrofurantoin course. Although fosfomycin resistance among uropathogens remains low—often below 5% in surveillance data—the drug’s pharmacokinetics are inconsistent, with urinary concentrations varying widely between patients. This variability can translate into sub‑therapeutic exposure for a subset of women, potentially explaining the observed efficacy gap.

For prescribers, the emerging evidence calls for a nuanced approach that balances convenience, resistance pressure, and patient outcomes. Nitrofurantoin’s longer course may be marginally less convenient, but its superior cure rates and predictable urinary concentrations make it a more reliable choice for most uncomplicated cases. Incorporating these data into antimicrobial‑stewardship programs can reduce unnecessary retreatments and curb the selection of resistant strains, ultimately preserving the utility of both agents in community practice. Ongoing research into novel oral agents, such as gepotidacin, may further expand the short‑course arsenal, but until broader efficacy data emerge, nitrofurantoin should remain the cornerstone of uncomplicated UTI therapy.